TB Archives – Page 2 of 48 – Treatment Action Group

An Activist’s Guide to Rifapentine – TB Preventive Treatment: 3HP and 1 HP

May 10, 2024
Dorrit Walsh

Rifapentine, an off-patent drug that's been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.

Director of Development

May 10, 2024
Dorrit Walsh

Treatment Action Group (TAG) seeks a dynamic, motivated, and skilled individual to become its Director of Development supporting the organization as it continues to grow.

Treatment Action Group Welcomes Two New Board Members

May 8, 2024
Dorrit Walsh

Treatment Action Group (TAG) is pleased to announce that two new members have been elected to the Board of Directors, Ama Burnham and Dr. Stefan V. Goldberg.

Going Behind the Scenes at TAG

May 7, 2024
Dorrit Walsh

Follow along with one of our staff members on a typical day, and you'll see the difference you make as a TAG donor and partner.

1/4/6×24 Mid-Campaign Report Launch Webinar

March 27, 2024
Dorrit Walsh

On March 27, 2024, the 1/4/6x24 Campaign and the Stop TB Partnership co-hosted a webinar to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments.

Mid-Campaign Report Highlights What’s Needed to Win Better, Shorter TB Treatments for All by End of 2024

March 22, 2024
Dorrit Walsh

Universal implementation of the best available treatment for drug-susceptible tuberculosis (TB) stands to cut 6.3 million years off total treatment by 2030, a new analysis released today by the 1/4/6x24 Campaign coalition has found.

Cover image of the publication: Getting Better Faster - Delivering on the Promise of New TB Treatments

Getting Better Faster: Delivering on the Promise of New TB Treatments – A Report from the 1/4/6×24 Campaign

March 21, 2024
Dorrit Walsh

This report marks the midway point of the 1/4/6x24 Campaign, which calls for the universal implementation of best available TB regimens — as little as one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.

Research in Action Awards 2024

March 18, 2024
Dorrit Walsh

Save the Date: Thursday, October 17, 2024, when our Research in Action Awards return this fall! Once again we'll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV).

2024 CROI Tuberculosis Research Round Up

March 14, 2024
Dorrit Walsh

Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). The highlights presented here cover the results of several phase II TB prevention and treatment trials.

Policy Issue Briefs: BARDA and ARPA-H

March 11, 2024
Dorrit Walsh

These two policy briefs explore two as yet untapped sources for drug-resistant tuberculosis (DR-TB) research funding within the U.S. Department of Health and Human Services (HHS).